MDR

This page shows the latest MDR news and features for those working in and with pharma, biotech and healthcare.

Merck preps regulatory filings for much-needed antibiotic combo

An independent UK review estimated that by 2050 MDR infections could claim 10 million lives a year and result in a cumulative loss from global output of $100trn. ... rates of multidrug resistant (MDR) strains, the need for new treatment options is

Latest news

Pharma must do more on antibiotic resistance, Davos meeting hears

In particular, more needs to be done to bring forward new drugs for multidrug resistant (MDR) pathogens or ‘superbugs’ - there are currently 28 novel drugs for high-priority pathogens in phase
Pfizer launches antibiotic resistance surveillance website

Meanwhile, Pfizer’s new antibiotic for multidrug resistant (MDR) infections, Zavicefta, was launched in its first European markets earlier this year after the pharma firm paid its developer AstraZeneca $1.58bn
Pfizer launches new antibiotic Zavicefta in UK and Germany

MDR infections are an increasing global threat," said Matteo Bassetti, chief of the infectious diseases Clinic at University of Udine in Italy. ... The availability of Zavicefta is a major step forward for physicians faced with the challenge of treating
AZ slims down again with sale of antibiotics to Pfizer

ATM-AVI is in trials for life-threatening Gram-negative bacterial infections caused by multi-drug resistant (MDR) strains, while CXL has activity against MDR Gram-positive and Gram-negative pathogens.
AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections. AstraZeneca's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been approved for marketing in the EU. ... In 2014 Professor Sally Davies, the UK Chief

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Medical device regulation - a risk-based approach to compliance

Simply put, complying with MDR is another stressor for medtechs at an already challenging time, potentially affecting both top- and bottom-line growth. ... It's difficult to estimate just how great the costs associated with MDR implementation will